ESG / Impact approach
Essange Reagents: Revolutionizing Diagnostics for Better Lives
Essange Reagents impacts patients globally by offering a wide range of immune and blood typing reagents. This innovative healthcare company plays a pivotal role in revolutionizing diagnostics and improving outcomes for patients globally.
Essange Reagents addresses a spectrum of diagnostic needs with a primary focus on immune reagents. Tests produced by the company are, for example, used in the detection of autoimmune disorders and bone marrow cancer. For those battling autoimmune disorders, the journey to diagnosis is often arduous, laden with deteriorating quality of life, financial strain, and the potential for severe consequences if diagnosis is delayed. “The burden for patients with bone marrow cancer is high, ” as [Janneke Lijbers, manager production] at Essange explains.
MORE...We distinguish between ESG (Environmental, Social, and Governance) and Impact, recognizing them as distinct and complementary elements. ESG forms the foundation of our responsible investment approach, encompassing environmental stewardship, social responsibility, and robust governance practices within the companies we support.
Big Health's Sleepio Revolutionizes Insomnia Care
In a world where insomnia affects one third of adults yearly, Big Health emerges as a game-changer with its revolutionary app Sleepio. Every year, millions of people suffer from insomnia, which profoundly impacts their quality of life. Sleep is a fundamental component of overall well-being and a lack of it can lead to a cascade of physical, emotional, and cognitive challenges.
Insomnia also imposes significant costs on society, including workplace productivity losses due to absenteeism and decreased efficiency, increased healthcare expenditures related to diagnostics and treatments, and elevated risks of accidents leading to additional societal expenses.
MORE...In a world where insomnia affects one third of adults yearly, Big Health emerges as a game-changer with its revolutionary app Sleepio. Every year, millions of people suffer from insomnia, which profoundly impacts their quality of life. Sleep is a fundamental component of overall well-being and a lack of it can lead to a cascade of physical, emotional, and cognitive challenges.
Insomnia also imposes significant costs on society, including workplace productivity losses due to absenteeism and decreased efficiency, increased healthcare expenditures related to diagnostics and treatments, and elevated risks of accidents leading to additional societal expenses.
Alignment with international standards
The values and foundations of our investment activities are based on the universal sustainability principles of the United Nations Global Compact. We expect all our immediate stakeholders to support these principles. Moreover, Gilde Healthcare is a signatory of the internationally recognized Principles of Responsible Investment (PRI) since 2019. Accordingly, we demonstrate our commitment to responsible investment through our participation in a publicly available annual report on our responsible investment activity. An important benefit of being a PRI signatory is access to a platform where best practices are shared among responsible investment professionals. Furthermore, all our investments in healthcare companies address the social needs of society and more specifically on United Nations Sustainable Development Goal 3 (SDG 3): Ensure healthy lives and promote well-being of all at all ages.
